| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2801903801019 | 190380101 | SUPERAMIN INJ.SOL 1G/5ML AMP BTX5 (AMPX5ML) | 3.33 | 3.49 | 4.81 |
| 05/2018 | 2801903804010 | 190380401 | SUPERAMIN INJ.SOL 2G/5ML AMP BT x 5 AMPS x 5 ML | 4.89 | 5.13 | 07.07 |
For treatment of primary systemic carnitine deficiency, a genetic impairment of normal biosynthesis or utilization of levocarnitine from dietary sources, or for the treatment of secondary carnitine deficiency resulting from an inborn error of metabolism such as glutaric aciduria II, methyl malonic aciduria, propionic acidemia, and medium chain fatty acylCoA dehydrogenase deficiency. Used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. Parenteral levocarnitine is indicated for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease.
Levocarnitine can be synthesised within the body from the amino acids lysine or methionine. Vitamin C (ascorbic acid) is essential to the synthesis of carnitine. Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. Levocarnitine is handled by several proteins in different pathways including carnitine transporters, carnitine translocases, carnitine acetyltransferases and carnitine palmitoyltransferases.
LD<sub>50</sub> > 8g/kg (mouse, oral). Adverse effects include hypertension, fever, tachycardia and seizures.
Absolute bioavailability is 15% (tablets or solution).
17.4 hours (elimination) following a single intravenous dose.